Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical classification of vasculitis.

Cord Sunderkötter1, Anca Sindrilaru

  • 1Department of Dermatology and Venerology, University Hospital of Münster, Von-Esmarch-Str. 58, 48129 Münster, Germany. cord.sunderkoetter@ukmuenster.de

European Journal of Dermatology : EJD
|April 4, 2006
PubMed
Summary

Accurate clinical classification of vasculitis, particularly leukocytoclastic vasculitis (LcV), aids diagnosis and management. Updated systems distinguish LcV subtypes for better patient stratification and treatment decisions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cefazolin as an alternative in patients with a history of penicillin or β-lactam antibiotic allergy: A case overview.

Allergologie select·2026
Same author

S1 Guideline on Infected Interdigital Intertrigo (also called Gram-Negative Toe Web Infection).

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026
Same author

Idiopathic cutaneous immunoglobulin G/immunoglobulin M vasculitis is likely a distinct entity: A European multicentric retrospective study.

JAAD international·2026
Same author

Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study.

International journal of cancer·2026
Same author

COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma.

Cancers·2026
Same author

A Pathway to High Quality Clinical Trials in IgA Vasculitis Nephritis: Meeting Proceedings From a Multiprofessional International Collaborative Workshop.

Kidney international reports·2026

Area of Science:

  • Rheumatology
  • Immunology
  • Dermatology

Background:

  • Clinical classification of vasculitis is crucial for diagnosis, management, and research.
  • Vessel size and caliber are key determinants of vasculitis clinical presentation.
  • Existing classification systems (ACR, CHCC) require updates, especially for leukocytoclastic vasculitis (LcV).

Purpose of the Study:

  • To provide an updated clinical classification of vasculitis, focusing on cutaneous manifestations.
  • To highlight the importance of distinguishing LcV subtypes for prognostic, diagnostic, and therapeutic purposes.
  • To guide decisions regarding diagnostic workup, treatment intensity, and prompt initiation of therapy.

Main Methods:

  • Review and update of existing American College of Rheumatology (ACR) and Chapel Hill Consensus Conference (CHCC) classification criteria.

Related Experiment Videos

  • Focus on vasculitic syndromes with regular cutaneous symptoms.
  • Integration of vessel size and type into classification.

    • Main Results:

    • Panarteritis nodosa (PAN) involves medium vessels, causing nodules and livedo racemosa, but not glomerulonephritis.
    • Leukocytoclastic vasculitis (LcV) affects small vessels, presenting as palpable purpura and potentially glomerulonephritis.
    • Distinctions within LcV, such as IgA-associated (Henoch-Schoenlein purpura, HSP) versus IgG/IgM-associated, and pediatric versus adult HSP, are critical for risk stratification.

    Conclusions:

    • An updated classification of vasculitis, emphasizing LcV subtypes, is essential for improved patient care.
    • Differentiating LcV forms impacts diagnostic strategies and therapeutic aggressiveness.
    • Prompt treatment is indicated for severe, ANCA-associated vasculitis.